Seeking Alpha

Teva gets FDA nod for generic TOBI

  • The FDA approves Teva's (TEVA -0.9%) generic version of the Novartis (NVS -0.2%) CF treatment TOBI.
  • TEVA expects to launch the product late next month.
  • TOBI had annual U.S. sales of ~$350M. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: